Treatment of Drug-Resistant Relapsed Non-Small Cell Lung Cancer Guided by Patient-Derived Organoid Drug Sensitivity 公告 2024-12-17 17:15:58 Written By Kym Kilbourne Title: Treatment of Drug-Resistant Relapsed Non-Small Cell Lung Cancer Guided by Patient-Derived Organoid Drug Sensitivity ClinicalTrials.gov ID: NCT06406608 Sponsor: Henan Cancer Hospital Provider of Information: Henan Cancer Hospital (Responsible Party) Last Update Posted: 2024-05-09 Study Overview Brief Summary This study aims to recruit non-small cell lung cancer patients who have received at least two rounds of standard treatment for drug resistance/relapse. Patient-derived organoids will be used to establish drug sensitivity tests to guide the selection of clinical treatment plans. Efficacy evaluation and prognosis analysis will also be conducted. It is hoped that this study will provide a basis for developing personalized treatment plans. Detailed Description Twenty patients with drug-resistant/relapsed non-small cell lung cancer who meet the inclusion criteria will be included in the study after signing an informed consent form. Tumor samples will be obtained through clinical punctures, and qualified samples will undergo organoid modeling. Drug sensitivity tests will be conducted on established lung cancer organoids. The drugs used are all marketed and clinically applied. Patients will receive treatment plans with relatively sensitive drugs based on the results of organoid drug sensitivity analysis. Follow-up data on the prognosis of enrolled patients and related clinical information will be collected to statistically analyze the consistency between drug sensitivity test results and patient treatment responses, and to assess the clinical effectiveness of treatment plans guided by organoid drug sensitivity results. Official Title Treatment of Drug-Resistant Relapsed Non-Small Cell Lung Cancer Guided by Patient-Derived Organoid Drug Sensitivity Conditions Non-Small Cell Lung Cancer Interventions/Treatments Other: Chemotherapy and targeted therapy guided by organoid drug sensitivity tests Other Study ID Numbers 2024-107 Contact and Location Information Study Contact Name: Wang Qiming, PhD Phone: +8613783590691 Email: qimingwang1006@126.com Study Link: https://clinicaltrials.gov/study/NCT06406608?term=organoid%20Guided&aggFilters=status:rec&rank=8 Kym Kilbourne
Treatment of Drug-Resistant Relapsed Non-Small Cell Lung Cancer Guided by Patient-Derived Organoid Drug Sensitivity 公告 2024-12-17 17:15:58 Written By Kym Kilbourne Title: Treatment of Drug-Resistant Relapsed Non-Small Cell Lung Cancer Guided by Patient-Derived Organoid Drug Sensitivity ClinicalTrials.gov ID: NCT06406608 Sponsor: Henan Cancer Hospital Provider of Information: Henan Cancer Hospital (Responsible Party) Last Update Posted: 2024-05-09 Study Overview Brief Summary This study aims to recruit non-small cell lung cancer patients who have received at least two rounds of standard treatment for drug resistance/relapse. Patient-derived organoids will be used to establish drug sensitivity tests to guide the selection of clinical treatment plans. Efficacy evaluation and prognosis analysis will also be conducted. It is hoped that this study will provide a basis for developing personalized treatment plans. Detailed Description Twenty patients with drug-resistant/relapsed non-small cell lung cancer who meet the inclusion criteria will be included in the study after signing an informed consent form. Tumor samples will be obtained through clinical punctures, and qualified samples will undergo organoid modeling. Drug sensitivity tests will be conducted on established lung cancer organoids. The drugs used are all marketed and clinically applied. Patients will receive treatment plans with relatively sensitive drugs based on the results of organoid drug sensitivity analysis. Follow-up data on the prognosis of enrolled patients and related clinical information will be collected to statistically analyze the consistency between drug sensitivity test results and patient treatment responses, and to assess the clinical effectiveness of treatment plans guided by organoid drug sensitivity results. Official Title Treatment of Drug-Resistant Relapsed Non-Small Cell Lung Cancer Guided by Patient-Derived Organoid Drug Sensitivity Conditions Non-Small Cell Lung Cancer Interventions/Treatments Other: Chemotherapy and targeted therapy guided by organoid drug sensitivity tests Other Study ID Numbers 2024-107 Contact and Location Information Study Contact Name: Wang Qiming, PhD Phone: +8613783590691 Email: qimingwang1006@126.com Study Link: https://clinicaltrials.gov/study/NCT06406608?term=organoid%20Guided&aggFilters=status:rec&rank=8 Kym Kilbourne
